Protalix BioTherapeutics, Inc. has appointed Dror Bashan as president and chief executive officer, and director, effective June 30, 2019.  He succeeds Moshe Manor, who is stepping down but will assist with the transition and continue to work with the company as a consultant. Mr. Bashan has more than 20 years of experience in the pharmaceutical industry with roles ranging from business development, marketing, sales and finance providing him with cross regional and experience and knowledge of t...